Sanofi Stock Euronext Paris
Stocks
SANNV
FR001400M6Z3
Pharmaceuticals
OTC Markets Traded| Market Cap | 85.63B 97.24B 81.13B 73.24B 138B 9,323B 140B 971B 374B 4,766B 365B 357B 15,281B | P/E 2026 * |
11.4x | P/E 2027 * | 9.92x |
|---|---|---|---|---|---|
| Enterprise Value | 97.09B 110B 91.99B 83.05B 157B 10,571B 159B 1,101B 424B 5,404B 414B 405B 17,326B | EV / Sales 2026 * |
2.04x | EV / Sales 2027 * | 1.86x |
| Free-Float |
88.34% | Yield 2026 * |
5.95% | Yield 2027 * | 6.29% |
Last Transcript: Sanofi
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/05/2026 | |
| Director of Finance/CFO | 64 | 01/04/2024 | |
Paulo Fontoura
CTO | Chief Tech/Sci/R&D Officer | - | 01/09/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 30/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 56 | 28/04/2020 |
Lise Kingo
BRD | Director/Board Member | 65 | 28/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 97.03B | |
| -1.49% | +1.79% | +53.55% | +117.65% | 1,056B | |
| -0.64% | -1.10% | +43.57% | +71.58% | 645B | |
| -0.08% | -0.74% | +13.64% | +77.48% | 465B | |
| -2.22% | -1.05% | +74.59% | +42.89% | 368B | |
| -0.06% | -3.88% | +34.32% | +40.74% | 335B | |
| -0.79% | +2.01% | +19.82% | +28.48% | 275B | |
| -1.19% | -1.21% | +9.82% | +12.15% | 255B | |
| -0.53% | +4.09% | +49.78% | +58.72% | 229B | |
| -0.73% | -0.83% | +35.23% | +102.58% | 188B | |
| Average | -0.72% | +0.12% | +37.15% | +61.36% | 423.98B | |
| Weighted average by Cap. | -0.91% | +0.30% | +40.86% | +73.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.65B 54.11B 45.15B 40.76B 76.82B 5,188B 77.81B 540B 208B 2,652B 203B 199B 8,503B | 50.64B 57.51B 47.98B 43.32B 81.65B 5,514B 82.7B 574B 221B 2,819B 216B 211B 9,038B |
| Net income | 7.48B 8.49B 7.09B 6.4B 12.06B 814B 12.21B 84.78B 32.62B 416B 31.89B 31.19B 1,335B | 8.89B 10.09B 8.42B 7.6B 14.33B 968B 14.51B 101B 38.76B 495B 37.89B 37.06B 1,586B |
| Net Debt | 11.46B 13.02B 10.86B 9.81B 18.48B 1,248B 18.72B 130B 50.01B 638B 48.88B 47.81B 2,046B | 8.34B 9.47B 7.9B 7.13B 13.44B 908B 13.61B 94.49B 36.36B 464B 35.55B 34.77B 1,488B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
